EPM
VRTX icon

Equitec Proprietary Markets’s Vertex Pharmaceuticals VRTX Stock Holding History

Equitec Proprietary Markets’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,171
Closed -$258K – 527
2014
Q4 		$258K Buy
+2,171
New +$245K 0.01% 247

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Equitec Proprietary Markets's VRTX Position: Q1 2015 in Review

Equitec Proprietary Markets sold out of Vertex Pharmaceuticals (VRTX) in Q1 2015, closing a stake of 2,171 shares — an estimated $258K sold.

Equitec Proprietary Markets first reported a position in VRTX in Q4 2014 and held it in 1 quarter. The position peaked at $258K in Q4 2014. 479 funds tracked by Wall St. Rank hold VRTX as of Q1 2015.

  • Equitec Proprietary Markets reported no remaining Vertex Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Equitec Proprietary Markets sold 2,171 Vertex Pharmaceuticals shares in Q1 2015, an estimated $258K.
  • Equitec Proprietary Markets first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Equitec Proprietary Markets's Vertex Pharmaceuticals position peaked at $258K in Q4 2014.
  • 479 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2015.

Based on Equitec Proprietary Markets's 13F filing for Q1 2015, filed 7 May 2015.